Healthcare & Biotech Sector Deep Dive — LLY, UNH, ABBV
Same sector, three completely different recovery stories
① Eli Lilly is a growth-stock-style healthcare name, holding a 60% share of the obesity-drug market and now armed with an FDA-approved oral GLP-1 pill.
② UnitedHealth is a recovery story — its stock is up 79% in a year after a 2025 medical-cost crisis, though a DOJ investigation remains a tail risk.
③ AbbVie is a transition story, successfully replacing patent-expired Humira with Skyrizi and Rinvoq.
① Introduction — why three different stories are unfolding at once
Healthcare is often lumped together as a single "defensive sector," but over the past year, Eli Lilly (LLY), UnitedHealth (UNH), and AbbVie (ABBV) have taken wildly different paths. Lilly has traded like a growth stock, creating an entirely new obesity-drug market. UnitedHealth is the textbook recovery stock, rebounding after its worst-ever earnings crisis in 2025. AbbVie is a transition stock, having successfully filled the revenue hole left by its flagship drug's patent expiration with new blockbusters.
This report breaks down each company's narrative, then closes with a framework for viewing the healthcare sector as a whole and a checklist for what Korean investors should verify right now.
② Eli Lilly — the dominant obesity-drug leader, now with a pill
Eli Lilly's stock is up 51.8% over the past year. The growth engine is its GLP-1 franchise — Zepbound and Mounjaro, for obesity and diabetes respectively. As of Q3 2025, Zepbound captured 71% of new US obesity prescriptions, well ahead of rival Novo Nordisk's Wegovy, and the Cardiometabolic Health segment (which includes both drugs) generated nearly $40 billion in 2025 revenue alone.
April 2026 brought another inflection point: FDA approval for Foundayo (orforglipron), an oral GLP-1 drug. Unlike most existing GLP-1 treatments, which are injections, Foundayo is a once-daily pill with no food or water restrictions — a major accessibility upgrade. Its Phase 3 ATTAIN trial showed weight loss of up to 12.4% (about 27 pounds) over 72 weeks, and Lilly priced it as low as $25/month for insured patients or from $149/month for self-pay, aiming to widen access.
| Eli Lilly (GLP-1) | Novo Nordisk (rival) | |
|---|---|---|
| Flagship products | Zepbound/Mounjaro (injectable) + Foundayo (oral) | Wegovy (injectable) + oral Wegovy tablet |
| Past-year stock performance | +58% | -5% |
| Share of new US obesity Rx | ~71% (as of Q3 2025) | Remainder |
| 2026 strategy | Expand oral options to widen access and adherence | Launch oral option to fight back |
The global obesity-drug market is projected to grow from $66 billion in 2025 to $120 billion by 2030. Lilly's commanding lead in this market is the core driver behind its recent stock strength.
③ UnitedHealth — from 2025's worst crisis to a one-year comeback
UnitedHealth's story is completely different from the other two. In Q3 2025, its medical cost ratio spiked to 89.9%, sending the stock to a 52-week low of $234.60. The medical cost ratio measures the share of premium revenue spent on actual medical claims — the higher it climbs, the worse an insurer's profitability.
But in 2026, the company staged a rapid recovery through contract repricing and efficiency gains at its Optum unit. The medical cost ratio fell to 83.9%, and management raised full-year 2026 adjusted EPS guidance to $19.50–$20.00. The stock has rallied 73% off its low, and its 79% one-year gain is the steepest of the three healthcare names covered here.
④ AbbVie — meeting Humira's patent cliff head-on with Skyrizi and Rinvoq
AbbVie's story is a textbook case of "how do you keep growing after losing your flagship product?" Humira, once the world's best-selling drug, saw revenue collapse as biosimilar competition intensified from 2023 onward. In Q2 2026, Humira revenue fell 35.9% year over year to $756 million, with the US decline running even sharper at 47%.
AbbVie had already prepared for this cliff by building up successor immunology drugs Skyrizi and Rinvoq. In Q2 2026, combined revenue from the two reached $8.03 billion (Skyrizi $5.51B, +24.4%; Rinvoq $2.53B, +24.5%) — comfortably outpacing Humira's decline. Skyrizi and Rinvoq alone now account for roughly 47% of total company revenue.
| Product | Q2 2026 Revenue | YoY | Notes |
|---|---|---|---|
| Humira | $756M | -35.9% | Biosimilar competition; US -47% |
| Skyrizi | $5.51B | +24.4% | Psoriasis, Crohn's, etc. |
| Rinvoq | $2.53B | +24.5% | Rheumatoid arthritis, etc. |
Wall Street projects AbbVie's annual revenue growing steadily from roughly $67 billion in 2026 to about $84 billion by 2030, with EPS rising from $14.25 in 2026 toward $20 by 2030. Its 32.5% one-year stock gain is the most modest of the three — but that can also be read as a stable move reflecting an already-proven transition, rather than an unresolved bet.
⑤ Side-by-side comparison
| Eli Lilly (LLY) | UnitedHealth (UNH) | AbbVie (ABBV) | |
|---|---|---|---|
| Investment character | Growth stock | Turnaround/recovery stock | Transition/repositioning stock |
| Core driver | Obesity-drug leadership + oral pill | Medical cost ratio improvement + efficiency gains | Successor drugs (Skyrizi, Rinvoq) |
| Past-year stock performance | +51.8% | +78.9% | +32.5% |
| Key risk | Intensifying competition (Novo Nordisk), valuation | DOJ investigation, sustainability of the recovery | Continued decline in residual Humira revenue |
| Best fit for | Investors who believe in the innovation/growth story | Investors seeking a bottom-fishing turnaround bet | Investors wanting a stable dividend and a completed transition |
⑥ How to view the healthcare sector as a whole — defense and growth coexist
Painting the healthcare sector with a single brush is risky. Within it sits Eli Lilly, a growth company creating new markets; UnitedHealth, a cyclically sensitive insurer whose results swing with policy and utilization trends; and AbbVie, a patent-cycle transition company whose revenue mix shifts as products come off patent. Investing in a healthcare ETF (XLV) versus an individual stock carries an entirely different risk-and-return profile — worth keeping in mind.
① Business-model axis — First, classify the company: drug developer, insurer/services provider, or pharma company with patent-cliff exposure.
② Regulatory-risk axis — Check drug pricing policy, Medicare/Medicaid-related rules, and any antitrust or DOJ scrutiny.
③ Pipeline axis — Always check what's queued up behind the products currently driving revenue (successor drugs, clinical-trial stage).
⑦ A checklist for Korean investors
① Check whether recent earnings included a guidance raise or cut — all three names saw guidance direction move the stock sharply.
② For turnaround names (like UNH), verify both the sustainability of the recovery and any regulatory risk.
③ For transition names (like ABBV), the key question is whether successor-product growth is outpacing the decline of the patent-expired product.
④ For growth names (like LLY), check every quarter whether the future growth already priced into the high valuation is actually materializing.
The moment you summarize healthcare as "defensive, therefore safe," you miss the completely different year these three stocks just had. Growth, recovery, and transition were each the result of taking on a different kind of risk. When picking a stock, read what page of which story the company is writing right now — not just the sector label on the tin.
※ This report is for informational purposes as of August 3, 2026 (data through July 31, 2026) and is not investment advice. Figures are drawn from each company's earnings releases, marketbrief's daily reports, and public reporting (Motley Fool, CNBC, BioSpace, TradingKey, and others). Investment decisions and responsibility rest with the investor.
※ This report is provided for informational and educational purposes only and does not constitute a recommendation to buy or sell any security.
New research, when it lands
Subscribe and the next deep dive comes to you, along with the daily market brief — free, unsubscribe anytime.